Occupational kidney cancer risk — which workplace chemicals matter, and which do not

It is not a separate disease. The tumour is the same renal cell carcinoma anyone else can develop; the phrase simply means that long-term exposure to something at work is thought to have contributed to it. Very few kidney cancers can be traced to a single cause, and in most people no trigger is ever identified. What we can say is that a small number of workplace substances, trichloroethylene most clearly among them, are linked to a modestly higher risk in people exposed to them regularly over years. Working in one of those trades does not mean you have kidney cancer, and it does not mean you will develop it.

The clearest is trichloroethylene, a chlorinated solvent used for degreasing metal and, historically, in dry cleaning, adhesives and printing. Cadmium is the metal most closely associated with kidney damage, and it is used in electroplating, nickel-cadmium batteries, pigments, and some soldering and smelting work. Other chlorinated solvents, arsenic, and heavy occupational doses of ionising radiation have all been studied, with weaker or less consistent findings for kidney cancer specifically. Several substances people assume are involved, including asbestos and petrol fumes, are not established kidney cancer risks, even though they cause harm elsewhere in the body. If you are unsure what you handled, your employer or occupational health service should hold the record.

Trichloroethylene is classified internationally as a substance that can cause cancer in humans, and the kidney is where the evidence is strongest. That evidence largely comes from workers exposed heavily and repeatedly, often for decades and at concentrations far above what modern workplace controls permit. Brief or occasional contact is a very different situation. If you spent years degreasing metal with solvents, mention it at your consultation and describe the work honestly: how often, for how long, in what ventilation, and with what protection. That history changes how a doctor weighs a symptom. On its own, it is not a reason for a scan.

Cadmium is unquestionably toxic to the kidney. It is absorbed slowly, stored in kidney tissue for many years, and long exposure can damage the filtering tubules, which often shows up first as protein in the urine. Whether it independently causes kidney cancer is less settled than it is for trichloroethylene, and study findings have not been consistent. The practical advice does not change either way. If you work with cadmium in electroplating, battery manufacture, pigments or soldering, use the protection and health monitoring your workplace provides, keep your kidney function checked, and tell any doctor treating you what you handle at work.

There is no population screening programme for kidney cancer, and a work history on its own is not an accepted reason for routine scanning. Scanning healthy people turns up a great many harmless cysts and small benign lumps, and each one brings further scans and further worry. Planned surveillance is reserved for defined high-risk groups, such as people with a confirmed inherited kidney cancer syndrome, a strong family history, or advanced kidney disease and long-term dialysis. NCCN guidance uses similar criteria when it recommends genetic risk evaluation. The more useful step is a consultation where your exposure history, blood pressure, weight, kidney function and any symptoms are reviewed together, with imaging arranged only if something genuinely warrants it.

Cancers linked to occupational exposure typically take many years to develop, and decades often pass between the exposure and any diagnosis. That is why the evidence for these substances comes from workers followed across long careers, and why a recent job change or a single spill is not the kind of exposure being described. It also means that if your exposure ended long ago, there is nothing useful left to undo. What remains worth doing is dealing with the risks that are still active, keeping your blood pressure and kidney function under review, and having any new symptom looked at promptly rather than watching it for months.